Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Original Article
  • Published:

Involvement of Bcl-XL deamidation in E1A-mediated cisplatin sensitization of ovarian cancer cells

Oncogene volume 25, pages 2656–2665 (2006)Cite this article

Abstract

The adenovirus E1A protein has been shown to be involved in the potentiation of apoptosis induced by chemotherapeutic agents, yet the molecular events of E1A-mediated apoptosis are not very clear. A recent report has suggested that deamidation of the Bcl-XL protein inhibits its antiapoptotic ability and leads to apoptosis induced by alkylating agents in Rb-deficient tumor cells. Since Rb is known to interact with E1A, which interrupts Rb's normal function, we examined Bcl-XL deamidation and cell death induced by cisplatin in E1A transfectants. We found that the E1A transfectants became sensitive to cisplatin-induced apoptosis compared to the parental cells, SKOV3.ip1. Our data show that cisplatin treatment induced the modification of Bcl-XL in the E1A transfectants in dosage and time-dependent manner. Furthermore, phosphatase treatment had no effect on the level of Bcl-XL modification, whereas alkaline lysis buffer appeared to induce the same modification of Bcl-XL. Ectopic expression of the deamidated forms of Bcl- XL in SKOV3.ip1 cells revealed that the modification to the Bcl- XL protein molecules was deamidation. Expression of the E1A mutant (dl1108) which contains deletion at CR2 domain suppressed Bcl-XL deamidation and apoptosis induced by cisplatin. We also found that expression of the nondeamidated Bcl-XL protected E1A transfectants from apoptosis. These findings suggest that Bcl-XL deamidation contributes to E1A-mediated cisplatin sensitization in SKOV3.ip1 cells.

This is a preview of subscription content, access via your institution

Access options

Buy this article

  • Purchase on Springer Link
  • Instant access to full article PDF
Buy now

Prices may be subject to local taxes which are calculated during checkout

Figure 1
Figure 2
Figure 3
Figure 4
Figure 5
Figure 6
Figure 7
Figure 8
Figure 9

Similar content being viewed by others

References

  • Abraham RT, Acquarone M, Andersen A, Asensi A, Belle R, Berger F et al. (1995). Biol Cell 83: 105–120.

  • Agarwal R, Kaye SB . (2003). Nat Rev Cancer 3: 502–516.

  • Amundson SA, Myers TG, Scudiero D, Kitada S, Reed JC, Fornace Jr AJ . (2000). Cancer Res 60: 6101–6110.

  • Brader KR, Wolf JK, Hung MC, Yu D, Crispens MA, van Golen K et al. (1997). Clin Cancer Res 3: 2017–2024.

  • Chattopadhtyay D, Ghosh MK, Mal A, Harter ML . (2001). J Viol 75: 9844–9856.

  • Chau BN, Wang JYJ . (2003). Nat Rev Cancer 3: 130–138.

  • Chellappan S, Kraus VB, Kroger B, Munger K, Howley PM, Phelps WC et al. (1992). Proc Natl Acad Sci USA 89: 4549–4553.

  • Chen IT, Smith ML, O'Connor P, Fornace Jr AJ . (1995). Oncogene 11: 1931–1937.

  • Deng J, kloosterbooer F, Xia W, Hung MC . (2002). Cancer Res 62: 346–350.

  • Deverman BE, Cook BL, Manson SR, Niederhoff RA, Langer EM, Rosova I et al. (2002). Cell 111: 51–62.

  • Deverman BE, Cook BL, Manson SR, Niederhoff RA, Langer EM, Rosova I et al. (2003). Cell 115: 503.

  • Dignam JD, Lebovitz RM, Roeder RG . (1983). Nucl Acids Res 11: 1475–1488.

  • Duelli DM, Lazebnik YA . (2000). Nat Cell Biol 2: 859–862.

  • Frisch SM, Mymryk JS . (2002). Nat Rev Mol Cell Biol 3: 441–452.

  • Lee WP, Tai DI, Tsai SL, Yeh CT, Chao Y, Lee SD et al. (2003). Cancer Res 63: 6229–6236.

  • Lee WP, Wen Y, Varnum B, Hung MC . (2002). Oncogene 21: 329–336.

  • Nevins JR . (1992). Science 258: 424–429.

  • Poruchynsky MS, Wang EE, Rudin CM, Blagosklonny MV, Fojo T . (1998). Cancer Res 58: 3331–3338.

  • Robinson NE . (2002). Proc Natl Acad Sci USA 99: 5283–5288.

  • Robinson NE, Robinson AB . (2001). Proc Natl Acad Sci USA 98: 12409–12413.

  • Samuelson AV, Lowe SW . (1997). Proc Natl Acad Sci USA 94: 12094–12099.

  • Scheffner M, Munger K, Byrne JC, Howley PM . (1991). Proc Natl Acad Sci USA 88: 5523–5527.

  • Shao R, Karunagaran D, Zhou BP, Li K, Lo SS, Deng J et al. (1997). J Biol Chem 272: 32739–32742.

  • Shisler J, Duerksen-Hughes P, Hermiston TM, Wold WSM, Gooding LR . (1996). J Virol 70: 68–77.

  • Strausberg RL, Feingold EA, Grouse LH, Derge JG, Klausner RD, Collin FS et al. (2002). Proc Natl Acad Sci USA 99: 16899–16903.

  • Takehara T, Takahashi H . (2003). Cancer Res 63: 3054–3057.

  • Uneo NT, Bartholomeusz C, Herrmann JL, Estrov Z, Shao R, Andreeff M et al. (2000). Clin Cancer Res 6: 250–259.

  • Uneo NT, Yu D, Hung MC . (1997). Oncogen 10: 1053–1059.

  • Viniegra JG, Losa JH, Sanchez-Arevalo VJ, Cobo CR, Soria VMF, Cajal SR et al. (2002). Oncogene 21: 7131–7136.

  • Wang H, Draetta G, Moran E . (1991). Mol Cell Biol 11: 4253–4265.

  • White E . (1996). Genes Dev 10: 1–15.

  • White E . (2001). Oncogene 20: 7836–7846.

  • Whyte P, Buchkovich KJ, Horowitz JM, Friend SH, Raybuck M, Weinberg RA et al. (1988). Nature 334: 124–129.

  • Yu D, Wolf JK, Scanlon M, Price JE, Hung MC . (1993). Cancer Res 53: 891–898.

  • Zhao R, Yang FT, Alexander DR . (2004). Cancer Cell 5: 37–49.

Download references

Acknowledgements

We thank Wei-Tin Cheng for excellent technical assistance, Mien-Chie Hung for cell lines and plasmids, and Ralph Kirby for critical review of the manuscript. This work was supported by Research Grant NSC 92-2314-B-010-063 (to EITC) from National Science Council, Taiwan, and VTY92-P5-35 (to EITC) from Veteran General Hospital-Taipei, Taiwan.

Author information

Author notes

  1. C-Y Chang and Y-M Lin: These authors contributed equally to this work.

Authors and Affiliations

  1. Institute of Biotechnology in Medicine, National Yang-Ming University, Taipei, Taiwan

    C-Y Chang, Y-M Lin, H-H Hsu & E I T Chen

  2. Division of Internal Medicine and Cancer Center, Taipei Veterans General Hospital, Taipei, Taiwan

    W-P Lee

Authors
  1. C-Y Chang
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Y-M Lin
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. W-P Lee
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. H-H Hsu
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. E I T Chen
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to E I T Chen.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Chang, CY., Lin, YM., Lee, WP. et al. Involvement of Bcl-XL deamidation in E1A-mediated cisplatin sensitization of ovarian cancer cells. Oncogene 25, 2656–2665 (2006). https://doi.org/10.1038/sj.onc.1209294

Download citation

  • Received:

  • Revised:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/sj.onc.1209294

Keywords

This article is cited by

Search

Advanced search

Quick links